The effect of osteoporosis treatment on bone mass

Natasha M. Appelman-Dijkstra*, Ling Oei, Annegreet G. Vlug, Elizabeth M. Winter

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)
53 Downloads (Pure)


Over the last two decades there have been significant developments in the pharmacotherapy of osteoporosis. The therapeutic arsenal has expanded with monoclonal antibodies which have been developed based on discoveries of the molecular mechanisms underlying bone resorption and bone formation. Denosumab, the antibody binding RANKL, inhibits bone resorption, and romosozumab, the antibody binding sclerostin, inhibits bone resorption and stimulates bone formation as well. Both antibodies have shown potent anti-fracture efficacy in randomized clinical trials and this review will discuss the preclinical and clinical studies focusing on the effects on bone mass. After discontinuation of these antibodies, bone mineral density quickly returns to baseline and in the case of denosumab, discontinuation can not only induce rebound bone loss, but also the occurrence of vertebral fractures. Therefore, sequential antiresorptive therapy to maintain bone mass gains and anti-fracture efficacy is of utmost importance and will also be discussed in this review.
Original languageEnglish
Article number101623
JournalBest Practice & Research Clinical Endocrinology & Metabolism
Issue number2
Publication statusPublished - Mar 2022

Bibliographical note

Publisher Copyright:
© 2022 The Author(s)


Dive into the research topics of 'The effect of osteoporosis treatment on bone mass'. Together they form a unique fingerprint.

Cite this